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background
Polymorphisms in genes other than the cystic fibrosis transmembrane conductance
regulator (CFTR) gene may modify the severity of pulmonary disease in patients with
cystic fibrosis. 
methods
We performed two studies with different patient samples. We first tested 808 patients
who were homozygous for the ∆F508 mutation and were classified as having either se-
vere or mild lung disease, as defined by the lowest or highest quartile of forced expira-
tory volume in one second (FEV1), respectively, for age. We genotyped 16 polymorphisms
in 10 genes reported by others as modifiers of disease severity in cystic fibrosis and tested
for an association in patients with severe disease (263 patients) or mild disease (545).
In the replication (second) study, we tested 498 patients, with various CFTR genotypes
and a range of FEV1 values, for an association of the TGFb1 codon 10 CC genotype with
low FEV1.
results
In the initial study, significant allelic and genotypic associations with phenotype
were seen only for TGFb1 (the gene encoding transforming growth factor b1), particu-
larly the ¡509 and codon 10 polymorphisms (with P values obtained with the use of
Fisher’s exact test and logistic regression ranging from 0.006 to 0.0002). The odds ra-
tio was about 2.2 for the highest-risk TGFb1 genotype (codon 10 CC) in association
with the phenotype for severe lung disease. The replication study confirmed the asso-
ciation of the TGFb1 codon 10 CC genotype with more severe lung disease in compari-
sons with the use of dichotomized FEV1 for severity status (P=0.0002) and FEV1 values
directly (P=0.02).
conclusions
Genetic variation in the 5' end of TGFb1 or a nearby upstream region modifies disease
severity in cystic fibrosis.
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ystic fibrosis is a recessive genetic
disorder that reflects mutations in the cyst-
ic fibrosis transmembrane conductance
regulator (CFTR) gene.1 Classic cystic fibrosis re-
flects two loss-of-function alleles, whereas non-
classic cystic fibrosis is characterized by at least one
mutant CFTR allele that confers partial function and,
in most cases, better survival.
There is great variability of pulmonary pheno-
type and survival in cystic fibrosis, even among pa-
tients who are homozygous for the most prevalent
mutation, ∆F508.1,2 Although environmental influ-
ences may modify clinical disease, there is probably
additional genetic variation (i.e., the presence of
“modifier” genes3) that contributes to the expres-
sion of the final phenotype.
To assess the effect of non-CFTR genetic poly-
morphisms on the clinical phenotype, we studied
variants of 10 genes previously reported as modifi-
ers in cystic fibrosis, including genes encoding a1-
antiprotease (a1AP)4-8; angiotensin-converting en-
zyme (ACE)9; b2-adrenergic receptor (ADRb2)10; two
glutathione S-transferases (GSTM1 and GSTP1)11-13;
interleukin-10 (IL10)9; mannose-binding lectin 2
(MBL2)14-18; nitric oxide synthase 3 (NOS3)19; trans-
forming growth factor b1 (TGFb1)9,20; and tumor
necrosis factor a (TNFa).9,12 Chloride conductance
that is linked to genetic background may modu-
late the clinical phenotype in cystic fibrosis, but the
specific loci and genes have not been identified.21
In the initial study, we tested patients who were
homozygous for the ∆F508 mutation and had one
of the two extremes of phenotypes associated with
lung function (i.e., severe or mild impairment) on
the basis of the hypothesis that adverse and benefi-
cial genetic variants would be enriched, respective-
ly, in these two groups of disease severity. The clas-
sification of pulmonary function as severe or mild
(i.e., the lowest or highest quartile of lung function
for age) was confirmed by estimating final forced
expiratory volume in one second (FEV1) for each
patient on the basis of multiple spirometric mea-
surements during the five years before enrollment
(see the Supplementary Appendix, available with
the full text of this article at www.nejm.org). Geno-
types of the modifier variants were compared in the
groups of patients with the severe or mild pheno-
type, in a manner similar to a case–control design.
We replicated our findings in a different population
of patients with cystic fibrosis.
patients 
For the initial study, the sample consisted of pa-
tients with cystic fibrosis, enrolled from 44 sites,
who were homozygous for the ∆F508 mutation.
The 840 patients who were initially enrolled were
chosen because their FEV1 measurements were
in the lowest quartile or highest quartile for age
among ∆F508 homozygotes. The lung function in
275 of these patients was classified as severely im-
paired (lowest quartile), and that of 565 patients as
mildly impaired (highest quartile). A total of 32 pa-
tients were excluded because they had inadequate
spirograms (2 patients), were not homozygous for
the ∆F508 mutation (8), or did not have more than
a 90 percent probability of having lung function
congruent with that of others in the severe or mild
category (22) (see Validation of Subjects in the Sup-
plementary Appendix). There were 808 patients in
the final data set. No patient was excluded because
of race or ethnic background; 96.7 percent of the
patients were self-identified as white.
In the replication study, we tested 498 patients
whose sputum cultures were negative for Burkhol-
deria cepacia and who had CFTR genotypes associat-
ed with pancreatic exocrine insufficiency; 70.5 per-
cent were ∆F508 homozygotes. As in the initial
study, no patient was excluded because of race or
ethnic background. The majority of the patients in
the replication study were from a research study at
the University of North Carolina at Chapel Hill, Case
Western Reserve University in Cleveland, or the Hos-
pital for Sick Children in Toronto (Supplementary
Appendix). The study was approved by the biomedi-
cal institutional review board of the University of
North Carolina and the institutional review board of
each participating institution. Patients and parents
of minors provided written informed consent.
data collection
For the initial study, each patient received a unique
code that was used to allow data processing while
maintaining anonymity. Key data were obtained
from source documents, including pulmonary-
function reports from the previous five years, which
provided measurements of height and weight to
calculate body-mass index as an index of nutrition,
and sputum microbiologic testing during the pre-
vious three years. Other data were obtained on case-
c
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report forms. For the replication study, we used FEV1
data that were available at the sites (Supplementary
Appendix).
genotyping
For the initial study, genetic testing was performed
by sequencing a1AP-Z and MBL2 B, C, and D “null”
alleles; by single-nucleotide polymorphism (SNP)
technology (BeadArray, Illumina) for a1AP-S and
G1237A alleles, GSTP1, IL10, MBL2 promoter variants
X and Y, NOS3, and TGFb1; or by published meth-
ods for ACE, ADRb2, GSTM1, and TNFa (Supple-
mentary Appendix). MBL2 structural (null) variants
(B, C, and D) were combined to construct the O/O
genotype. Other possible modifier genes for lung
disease and their SNPs (65 and 135, respectively)
were genotyped by Illumina but were not examined
for the initial study. At least 798 patients were suc-
cessfully genotyped for most genetic variants, except
for four alleles: a1AP-Z (781 patients), two ADRb2
alleles (741 and 743 patients, respectively), and
TNFa (743 patients). For regions flanking TGFb1,
we tested 31 SNPs at the Genome Analysis Facility
at the University of North Carolina at Chapel Hill
(TaqMan SNP Genotyping Assay by ABI-7900HT,
Applied Biosystems) (Supplementary Appendix).
After correction for multiple testing, none of the
SNPs in the initial study showed significant overall
departure from Hardy–Weinberg equilibrium.22
For the replication study, TGFb1 codon 10 genotypes
were determined by sequencing (at the University
of North Carolina and Case Western Reserve Uni-
versity) and by allele-specific oligonucleotide test-
ing (at the Hospital for Sick Children) (Supplemen-
tary Appendix).
statistical analysis
For the initial study, the association between poly-
morphisms and the phenotype for the severity of
impairment of lung function was assessed with the
use of Fisher’s exact tests of genotype and allele
frequencies. All tests were two-sided, with an alpha
level of 0.05 considered to indicate statistical sig-
nificance. Unadjusted P values are reported, where-
as multiple-comparison corrections were performed
for the 16 polymorphisms by recomputing the tests
for 10,000 random permutations of severity-of-
impairment status. The adjusted P value was based
on the permutation distribution of the smallest
P value among the 16. 
For TGFb1 polymorphisms, estimated haplotype
reconstructions23 were compared with severity sta-
tus to compute standard contingency table (chi-
square) statistics. P values for these haplotypes were
assessed with the use of 10,000 random permuta-
tions of severity status. Logistic regression was used
to estimate the effect of TGFb1 genotypes on the
odds of a patient’s having the phenotype for severe
impairment under three genetic models (recessive,
codominant, and dominant). Additional multivari-
ate logistic-regression analyses included the covari-
ates of the presence or absence of diabetes mellitus,
Pseudomonas aeruginosa airway infection, meconium
ileus, and a physician’s diagnosis of asthma.24 Link-
age disequilibrium patterns among TGFb1 polymor-
phisms and 31 flanking SNPs were analyzed with
the use of E-M estimation of haplotype frequencies,
as implemented with the LDMAX program in the
GOLD software package.25,26 
For the replication study, we used results from
the initial study to guide the design and to establish
primary and secondary analytic approaches (Sup-
plementary Appendix). Analysis of the initial study
data suggested that the use of a dichotomized phe-
notype and a recessive model for an increased risk
of severity of impairment due to the codon 10 C al-
lele would provide the greatest power. The primary
analysis for the replication study was performed
with Fisher’s exact test of association between the
TGFb1 codon 10 CC genotype and FEV1 status be-
low or above a defined threshold (an FEV1 of 68 per-
cent of the predicted value, estimated for the age
of 20 years), with the use of a mixed linear regres-
sion model (Supplementary Appendix). In the sec-
ondary analysis in the replication study, we used a
Wilcoxon test to compare FEV1 values for patients
with the codon 10 CC genotype with those for pa-
tients with other (TC/TT) genotypes (Supplemen-
tary Appendix). As an additional conservative ap-
proach, two-sided P values were calculated for
both primary and secondary analyses of the repli-
cation data. To reduce multiple comparisons, asso-
ciation tests were performed only on the entire
sample in the replication study. Tests of Hardy–
Weinberg equilibrium were also performed with-
in groups that were classified according to the se-
verity of impairment of lung function,22 following
predictions that departures from Hardy–Weinberg
equilibrium can arise with associated genes in case–
control studies27 (Supplementary Appendix).
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The pulmonary and nutritional characteristics of
263 patients with the phenotype for severe impair-
ment of lung function were distinctly different from
those of 545 patients with the phenotype for mild
impairment (Table 1). Even though patients in the
group with the mild phenotype were approximate-
ly 12 years older than patients in the group with the
severe phenotype, the average FEV1 at enrollment
of patients with mild impairment was higher and
the yearly decline in FEV1 was approximately one
third of that in patients with severe impairment.
The group with the mild phenotype had relatively
preserved nutrition (on the basis of the body-mass
index), whereas the group with the severe pheno-
type was malnourished. The two groups were sim-
ilar with respect to the sex ratio; the presence or
absence of P. aeruginosa in sputum; diabetes melli-
tus (when adjusted for age) or asthma; and enroll-
ment site (86.4 percent of patients with the severe
phenotype were matched by enrollment of one or
more patients with the mild phenotype from the
same site). When we divided the mild group into
two age groups according to predetermined crite-
ria (Supplementary Appendix), there were even
more striking differences between the severe group
and the younger mild group with respect to FEV1
and its rate of decline. The patients in the older
mild group had FEV1 values similar to those of the
severe group, despite being approximately 22 years
older.
Genotype and Allelic Associations
In the analysis of previously reported genes (Ta-
ble 2), significant associations with phenotype were
results
* Plus–minus values are means ±SD. 
† P values were calculated with the Wilcoxon rank-sum test for continuous variables and the chi-square test for categori-
cal variables.
‡ Severe impairment was defined as being in the lowest 25th percentile of forced expiratory volume in one second (FEV1) 
for age, as compared with patients of the same age who were homozygous for the ∆F508 mutation.
§ Mild impairment was defined as being in the highest 25th percentile of FEV1 and survival (for older patients), as com-
pared with ∆F508 homozygotes the same age.
¶ Values reported are means and standard deviations of empirical Bayes estimates for individual patients, obtained by fit-
ting a mixed model to data from all 808 patients. The FEV1 percentage of predicted value is at the time of enrollment.
¿ The predicted survival was calculated from a combination of the patient’s age and best yearly FEV1 percentage of pre-
dicted value with the use of estimates derived from a joint model of lung function and survival.28
**The body-mass index was referenced to age- and sex-matched normal persons, of whom the 50th percentile was used 
as the median value.
††The presence of infection was determined by sputum culture.
‡‡The presence of diabetes was determined on the basis of an abnormal fasting glucose level, an abnormal result on a 
glucose-tolerance test, or the use of oral hypoglycemic agents or insulin.
§§ The presence of asthma was determined on the basis of criteria of the American Thoracic Society. 
Table 1. Characteristics of 808 Patients with Cystic Fibrosis Homozygous for the ∆F508 Mutation, According to 
the Phenotype for Severe or Mild Impairment of Lung Function and Age (Initial Study).*
Variable Degree of Impairment P Value†
Patients with Mild Impairment,










Range 8–25 15–55 15–28 29–55
Mean 16.2±4.1 28.6±9.7 <0.001 20.9±4.0 38.0±5.3
Sex (% male) 49.4 55.6 0.10 50.8 61.4
FEV1 (% of predicted value)¶ 46.6±16.1 72.4±28.1 <0.001 90.8±16.2 50.0±22.9
FEV1 decline (%/yr)¶ 3.65±2.20 1.35±1.51 <0.001 1.10±1.77 1.64±1.04
Median predicted survival (age in yr)¿ 31.4 56.6 <0.001 58.0 55.3
Body-mass index (percentile)** 19.6±21.7 44.0±26.1 <0.001 47.0±24.1 40.4±28.0
Positive test for P. aeruginosa (%)†† 89.0 86.1 0.25 84.0 88.6
Diabetes mellitus (%)‡‡ 15.6 24.0 0.006 14.1 36.2
Asthma (%)§§ 19.4 22.0 0.39 19.7 24.8
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seen only for TGFb1 variants; the codon 10 variant
had a multiple-comparison corrected P value of 0.01
(the most significant association among the 16 in
Table 2). The frequencies of the genotypes and “mi-
nor” alleles for genetic variants tested were similar
to those previously reported among white subjects
(Table 2).4-15,19,20,29-32 In further analyses of sub-
groups, there were four significant or suggestive
P values (between 0.01 and 0.10) for variants a1AP-Z
and GSTM1 (Table 1 in the Supplementary Appen-
dix); none of the P values were significant after mul-
tiple-testing corrections.
The TGFb1 variant genotypes were strongly as-
sociated with phenotype (Table 2). A statistical as-
sociation was also seen in a permutation test of
reconstructed haplotype frequencies for the three
TGFb1 SNPs (P=0.007). In tests of direct allelic as-
sociation, only two TGFb1 SNPs (¡509 and codon
10) were significant (P=0.009 and P=0.001, respec-
tively). The prevalence of two TGFb1 genotypes in
the severe and mild groups is shown in Figure 1.
Patients with the phenotype for severe impairment
of lung function were twice as likely to be homozy-
gous for the TT genotype of ¡509 and the CC geno-
type of codon 10.
Further analyses were undertaken with the use
of logistic regression for the two most significant
TGFb1 variants, with the use of three genetic mod-
els (recessive, codominant, or dominant) to test for
the effect of the higher-risk genotype on the odds
of having the severe phenotype (Table 3). The reces-
sive and codominant models were most highly sig-
nificant; for the recessive model, the odds ratios
for genotype effects were 2.18 and 2.25 for the over-
all analysis, and they ranged from 1.58 to 3.16 for
subgroup analyses by sex. Similar results were ob-
tained after adjustment for four covariates: the pres-
ence or absence of diabetes mellitus, meconium
ileus at birth, P. aeruginosa infection, and asthma
(Table 2 in the Supplementary Appendix).
SNPs Flanking TGFb1 and Linkage Disequilibrium 
Patterns
We reasoned that testing additional SNPs around
TGFb1 would further elucidate the genetic associa-
tion and linkage disequilibrium patterns (Fig. 1 in
the Supplementary Appendix). A total of 31 SNPs
surrounding TGFb1 were genotyped; Figure 1 dis-
plays the P values for the association of SNP gen-
otypes with the severity of disease (¡log10 scale),
shown according to genomic position. The TGFb1
variant codon 10 retained the strongest evidence
of an association with severity. Of the flanking SNPs,
only the two directly 5' of TGFb1 (7381 and 7045,
GenBank accession number NT_011109) were sig-
nificant, and those SNPs were in strong linkage
Figure 1. Prevalence and Association of TGFb1 Geno-
types in Groups Categorized According to Lung Impair-
ment (Initial Study).
In Panel A, patients with the pulmonary phenotype for 
severe impairment of lung function (dark blue bars, rep-
resenting 263 patients) were twice as likely to be ho-
mozygous for the TT genotype of ¡509 and the CC 
genotype of codon 10 as were patients with mild impair-
ment (medium blue bars, representing 299 patients be-
tween the ages of 15 and 28 years, and light blue bars, 
representing 246 patients who were 29 years of age or 
more). P values, calculated with Fisher’s exact test, are 
for the comparison between genotypes of patients with 
severe impairment of lung function and those of pa-
tients with mild impairment. Panel B shows P values 
(¡log10 scale) according to genomic position of the three 
TGFb1 variants that were initially tested and 31 single-
nucleotide polymorphisms (SNPs) in flanking regions. 
Five additional genes in the region with described func-
tions in the Swiss-Prot/TrEMBL protein-sequence data-
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disequilibrium with ¡509 and codon 10 (Fig. 1 of
the Supplementary Appendix). The results indicate
that these four SNPs belong to a haplotype “block”
and are congruent with lower-resolution data from
the International HapMap Consortium.33 The Har-
dy–Weinberg equilibrium tests within severity
groups provided further evidence of the recessive
action of the codon 10 CC genotype (Results sec-
tion of the Supplementary Appendix). These data
are consistent with an association between disease
severity and one or more founding polymorphisms
in the 5' end of TGFb1 or immediately upstream.
replication study
Among patients in the replication study, the dis-
tribution of sex, age, and FEV1 were representative
of a mixed pediatric and adult population of patients
with cystic fibrosis (Table 4). Primary genetic analy-
sis showed a strong association of the TGFb1 codon
10 CC genotype with lower FEV1 values when pa-
tients were divided into two groups according to
the FEV1 value with the use of criteria derived from
the initial study (FEV1 at age 20, <68 percent of the
predicted value or ≥68 percent) (Table 4 and Supple-
mentary Appendix). The prevalence of the CC geno-
type was two times as great among patients with
an FEV1 of less than 68 percent as among those
with an FEV1 of 68 percent or more (P=0.0002).
The result was not highly sensitive to the dichoto-
mization threshold, since P values of less than 0.01
were achieved for FEV1 thresholds ranging from 65
to 74 percent of the predicted value. The secondary
analysis also showed an association between codon
10 genotypes and FEV1 (P=0.02); specifically, the
FEV1 was lower in patients with the CC genotype
than in those with the TC/TT genotypes (62.8 per-
cent vs. 68.2 percent of the predicted value). Simi-
lar results were seen among patients who were strat-
ified according to whether they were homozygous
for the ∆F508 mutation (Table 4).
Studies have shown that multiple genetic polymor-
phisms act as modifiers of lung disease in cystic fi-
brosis, but these studies involved small numbers of
patients, patients with a broad range of CFTR geno-
types, or limited clinical phenotyping that did not
address long-term outcome (survival).4-17,19,20 To
increase the likelihood of identifying genetic mod-
ifiers that are relevant to the clinical outcome in cyst-
ic fibrosis, we performed two sequential studies in
discussion
* For each listed genetic variant, the higher-risk allele is indicated, and odds ratios are presented for the highest-risk gen-
otype as compared with the lowest-risk genotype. The number of patients (804) reflects the genotypes available. Specif-
ic genotype comparisons are listed below. CI denotes confidence interval.
† The value is for the comparison of the T/T genotype with the combined C/T and C/C genotypes.
‡ The value is for the comparison of the T/T genotype with the C/C genotype.
§ The value is for the comparison of the combined C/T and T/T genotypes with the C/C genotype.
¶ The value is for the comparison of the C/C genotype with the combined C/T and T/T genotypes.
¿ The value is for the comparison of the C/C genotype with the T/T genotype.
**The value is for the comparison of the combined C/C and C/T genotypes with the T/T genotype.
Table 3. Logistic-Regression Analysis of TGFb1 Genetic Variants Associated with Severe Lung Disease among Patients 
with Severe Impairment (N=260) and Mild Impairment (N=544) (Initial Study).*
Genetic Variant 
and Reference SNP Recessive Model Codominant Model Dominant Model
Odds Ratio 
(95% CI) P Value
Odds Ratio 
(95% CI) P Value
Odds Ratio 
(95% CI) P Value
All patients (N=804)
¡509 T (1800469) 2.25 (1.34–3.76) 0.002† 1.90 (1.19–3.01) 0.007‡ 1.30 (0.97–1.75) 0.08§
Codon 10 C (1982073) 2.18 (1.44–3.29) 0.0002¶ 2.10 (1.36–3.26) 0.0009¿ 1.37 (1.01–1.87) 0.04**
Male patients (N=430)
¡509 T (1800469) 2.25 (1.11–4.58) 0.02 1.97 (1.02–3.77) 0.04 1.32 (0.87–2.01) 0.19
Codon 10 C (1982073) 1.58 (0.88–2.81) 0.12 1.76 (0.95–3.27) 0.07 1.37 (0.88–2.12) 0.16
Female patients (N=374)
¡509 T (1800469) 2.25 (1.06–4.76) 0.04 1.89 (0.97–3.66) 0.06 1.31 (0.85–2.00) 0.22
Codon 10 C (1982073) 3.16 (1.70–5.84) 0.0003 2.60 (1.38–4.87) 0.003 1.42 (0.91–2.20) 0.12
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different samples of patients. The initial study test-
ed 10 candidate modifier genes, and the replication
study was performed to confirm TGFb1 as an im-
portant modifier in cystic fibrosis.
The initial study used an extreme phenotype
design (essentially case–control) with five key fea-
tures. First, to reduce genetic heterogeneity, we
studied only ∆F508 homozygotes. Second, on the
basis of the hypothesis that adverse (and beneficial)
genetic variants would segregate with severe (and
mild) lung disease, we studied patients at the ex-
tremes of lung function (lowest 25th percentile and
the highest 25th percentile for age). Third, the sever-
ity of lung function was determined with the use of
FEV1, the functional measure that best correlates
with clinical status and outcome.34,35 Fourth, the
classification of pulmonary status (severe vs. mild)
was confirmed by estimating final FEV1 for each pa-
tient on the basis of previous measurements of FEV1
during the five years before enrollment. Finally, a
large number of patients were enrolled in order to
improve statistical power. The sample was geneti-
cally homogeneous for ∆F508, and 96.7 percent of
the patients were white; thus, population stratifica-
tion is unlikely to have caused spurious association
with the phenotype.36
The sample population and design of the repli-
cation study differed from the initial study in the
following ways: most of the patients were from
three sites (the University of North Carolina at
Chapel Hill, Case Western Reserve University, or
the Hospital for Sick Children, Toronto), there was
a broad range of spirometric values (i.e., patients
were not selected solely from the extremes of phe-
notype), and the CFTR genotypes were mixed “pan-
creatic insufficient” mutations (approximately 70
percent were homozygous for the ∆F508 mutation).
The primary analysis for the replication study was
performed on the basis of the initial study, in which
the greatest association of the CC genotype with
phenotype was seen when a comparison was made
between patients whose FEV1 values were below 68
percent of the predicted value and those whose val-
ues were 68 percent of the predicted value or more.
Despite the differences in study design, sample
population, and analytic approach, the replication
study clearly confirmed that the TGFb1 codon 10 CC
genotype acted as an adverse modifier of lung dis-
ease in cystic fibrosis. Moreover, the magnitude of
the effect (odds ratio, approximately 2.2) was simi-
lar to that in the initial study. The adverse TGFb1 gen-
otypes that we report differ from those found in two
previous smaller studies in cystic fibrosis.9,20
In addition to the biologic plausibility of TGFb1
as a modifier of lung disease (see below), recent as-
sociation studies have linked TGFb1 polymorphisms
to asthma and chronic obstructive pulmonary dis-
ease.29-32 However, these studies involved relative-
ly few polymorphisms, leaving open the possibility
that the associations may be due to nearby causa-
tive genes in linkage disequilibrium with TGFb1.
Our inclusion of 31 SNPs flanking TGFb1 greatly
narrows the possibility of a modifier gene in the re-
gion (Fig. 1). The association evidence includes the
* Plus–minus values are means ±SD. The values for forced expiratory volume in one second (FEV1) are the empirical Bayes 
predicted values obtained for each patient at 20 years of age with the use of a mixed model, fitted to data from all 498 pa-
tients.
† P=0.0002 for the comparison with the prevalence of the CC genotype in patients with an FEV1 of 68 percent or more 
of the predicted value, by Fisher’s exact test.
‡ P=0.02 for the comparison with the mean FEV1 in patients with the TC/TT genotype, by the Wilcoxon rank-sum test.
Table 4. Characteristics of Patients and TGFb1 Codon 10 Genotypes Stratified According to FEV1 and Mean FEV1 
According to Codon 10 Genotype (Replication Study).* 
Variable All Patients ∆F508 Homozygotes
<68% ≥68% <68% ≥68%
CC genotype according to FEV1
No. of patients 246 252 184 169
Age (yr) 20.8±8.1 22.3±7.8 21.2±8.1 22.5±7.9
Male sex (%) 48.0 57.1 48.4 53.2
Codon 10 CC genotype (%) 23.6† 11.1 21.7 10.7
CC TC/TT CC TC/TT
FEV1 by codon 10 genotype
No. of patients 86 412 58 295
Mean FEV1 (% of predicted value) 62.8±21.3‡ 68.2±22.3 62.1±21.1 67.1±23.4
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5' end of TGFb1 and only one other gene (MGC4093)
of unknown structure and function, which lies be-
tween TGFb1 (¡509) and SNP number 7045. Tran-
scripts of MGC4093 have been reported in UniGene
libraries of lung tissue, but Celedon et al.32 argued
that MGC4093 could be ruled out as a modifier of
chronic obstructive pulmonary disease on the basis
of associations observed between TGFb1 and the
disease in two samples of white patients. One sam-
ple showed the greatest evidence among 3' TGFb1
SNPs, and the other sample showed the greatest
evidence among the 5' SNPs, ¡509 and codon 10.
The 3' SNPs exhibit little linkage disequilibrium
with the 5' SNPs,33 and Celedon et al. concluded that
their data implicated TGFb1 alone. Our genetic as-
sociations and patterns of linkage disequilibrium
are consistent with the report of Celedon et al., and
we propose TGFb1 as a likely modifier in another
disease of the lung (i.e., cystic fibrosis).
The gene most likely to modify the clinical phe-
notype in our study, TGFb1, has multiple functions
related to growth and differentiation, immune re-
sponses, proinflammatory and antiinflammatory
effects, and extracellular matrix production.37,38
TGFb1 has been implicated in the pathogenesis of
lung disease in animal models and humans, includ-
ing disease progression in idiopathic pulmonary
fibrosis, and in association with chronic obstruc-
tive pulmonary disease and asthma.29-32,39-41 The
association of the TGFb1 ¡509 T allele with asthma
is postulated to involve increased TGFb1 activity,
reflecting increased Yin Yang 1 binding and pro-
moter function and accompanied by higher circu-
lating levels of TGF-b1.30,31,42 The TGFb1 polymor-
phisms in our study that are associated with the
phenotype for severe impairment of lung function
in cystic fibrosis are compatible with the hypothe-
sis in asthma. Specifically, the ¡509 TT and the
codon 10 CC genotypes correlate with an increase
in gene expression, TGF-b1 secretion, and circu-
lating levels of TGF-b1.43-45 The specific cellular-
and organ-level pathophysiological mechanisms
of increased TGF-b1 activity in cystic fibrosis remain
to be defined. However, this association will guide
mechanistic studies and future strategies for ther-
apeutic intervention.
In striking contrast, these same TGFb1 alleles
(¡509 T and codon 10 C) are protective against
chronic obstructive pulmonary disease induced by
smoking.29,32 The magnitude of the increased prev-
alence of TGFb1 genotypes as adverse modifiers in
our studies of cystic fibrosis and in studies of asth-
ma,30,31 and as protective modifiers in chronic ob-
structive pulmonary disease,29,32 is consistent — in
other words, 12 to 14 percent prevalence for the
¡509 TT genotype and 19 to 22 percent for the codon
10 CC genotype. The contrast of TGFb1 polymor-
phisms as adverse modifiers in our studies of cystic
fibrosis and in asthma, as compared with the pro-
tective effect seen in smokers, indicates that the
same genetic polymorphisms may be protective or
adverse, depending on environmental and other
genetic factors.
In summary, we used two study designs and en-
rolled a large number of patients to test genes previ-
ously implicated as modifiers in cystic fibrosis. Of
these candidates, only TGFb1 variants were strongly
associated with pulmonary phenotypes that are
predictive of the long-term outcome. These TGFb1
polymorphisms are common in cystic fibrosis, and
the odds ratios for an association of the higher-risk
alleles with severe disease are relatively high (>2.0)
for a contribution of genetic modifiers to a men-
delian disorder. Thus, genetic variation in TGFb1
or the immediate upstream region is an important
genetic mechanism that modifies disease severity
and clinical outcome in cystic fibrosis.
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